Kolexia
Lena Herve Pneumologie
Lena Herve
Pneumologie
Hôpital Pontchaillou
Rennes, France
304 Activités
935 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Carcinomes Adénocarcinome Métastase tumorale Carcinome épidermoïde Mésothéliome Mésothéliome malin

Collaborateurs

Voir plus
Mazieres Julien
Mazieres Julien
Hôpital Rangueil, Toulouse, France
Chouaid Christos
Chouaid Christos
Centre Hospitalier Intercommunal Créteil, Créteil, France
Barlesi Fabrice
Barlesi Fabrice
Gustave-Roussy, Villejuif, France
Ricordel Charles
Ricordel Charles
Hôpital Pontchaillou, Rennes, France

Industries

Voir plus
A+A
44 collaboration(s)
Dernière en 2023
MSD
20 collaboration(s)
Dernière en 2023
AstraZeneca
17 collaboration(s)
Dernière en 2023
Sanofi
15 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE): Official Title: A Phase II Multicenter, Open Label, Non-randomized Study of Neoadjuvant and Adjuvant Treatment With IPH5201 and Durvalumab in Patients With Resectable, Early-stage (II to IIIA) Non-Small Cell Lung Cancer (MATISSE)
Essai Clinique (Innate Pharma)   13 mars 2024
SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
Essai Clinique (Lilly)   27 février 2024
MELROSE: Phase 2 Study Evaluating MEchanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtinib Until and Beyond Radiological Progression : the MELROSE Trial
Essai Clinique (AstraZeneca)   26 février 2024
BREC: Multicenter Phase III, Randomized Study to Evaluate Treatment Customized According to RAP80 and BRCA1 Assessment in Patients With Advanced Non-small-cell Lung Cancer
Essai Clinique (Spanish Lung Cancer Group)   29 janvier 2024
ATLANTIC: A Phase II,Non-comparative,Open Label, Multi-centre, International Study of MEDI4736, in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least 2 Prior Systemic Treatment Regimens Including 1 Platinum-based Chemotherapy Regimen
Essai Clinique (AstraZeneca)   17 janvier 2024
76P Immune checkpoint inhibitor (ICI) retreatment patterns and outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who received second-line or later (2L+) nivolumab (nivo): A French I-O optimise analysis
Abstract Book of the ESMO Immuno-Oncology Congress 2023 6-8 December 2023   01 décembre 2023
70P LIST (Lung Initiative on Sequence Therapy): A real-world study of nivolumab for advanced NSCLC in France - First effectiveness, safety, and IO-rechallenge results
Abstract Book of the ESMO Immuno-Oncology Congress 2023 6-8 December 2023   01 décembre 2023
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).: A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C
Essai Clinique (Amgen)   18 octobre 2023
Test de concordance de script et évaluation du raisonnement clinique pour les cancers bronchiques localement avancés: Script Concordance Test and assessment of clinical reasoning in locally advanced non-small cell lung cancer
Revue des maladies respiratoires actualites   01 octobre 2023
1359P Relationship between tumor TP53 gene mutation, circulating anti-p53 antibodies and response to first-line osimertinib in EGFR-mutated NSCLC patients
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023